WO2018185783A1 - Nouveau procédé de préparation de 19- norstéroïdes - Google Patents
Nouveau procédé de préparation de 19- norstéroïdes Download PDFInfo
- Publication number
- WO2018185783A1 WO2018185783A1 PCT/IN2018/050196 IN2018050196W WO2018185783A1 WO 2018185783 A1 WO2018185783 A1 WO 2018185783A1 IN 2018050196 W IN2018050196 W IN 2018050196W WO 2018185783 A1 WO2018185783 A1 WO 2018185783A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- norethisterone
- solution
- group
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title description 13
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims abstract description 42
- 239000002253 acid Substances 0.000 claims abstract description 15
- 239000003960 organic solvent Substances 0.000 claims abstract description 15
- 238000010992 reflux Methods 0.000 claims abstract description 8
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims abstract description 7
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 6
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- 150000001247 metal acetylides Chemical class 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- JRIZOGLBRPZBLQ-QXUSFIETSA-N 19-Norandrostenedione Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JRIZOGLBRPZBLQ-QXUSFIETSA-N 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 22
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 7
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 17
- 239000002585 base Substances 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000002875 norsteroids Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- -1 norsteroids compounds Chemical class 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-XUFBONQXSA-N (8r,9s,10r,13s,14r,17s)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-XUFBONQXSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
Definitions
- the present invention provides a process for the preparation of norsteroids.
- the present invention provides a process for the preparation of 19-norsteroids.
- Norsteroids are pharmacologically active compounds or important intermediate for pharmacologically active compounds. These have been known as xenobiotics with androgenic and anabolic properties and obligatory endogenous intermediates in the biosynthesis of estrogens from androgens in all species, including mammals.
- Norsteroids have been found to exhibit potent progestational activities, antiestrogenic activities, and estrogenic responses in the estrogen-deficient state. Besides, depending on the specific compound produced, there are several other effects also associated with that compound such as pregnancy-maintenance, anti-estrogenic, ovulation- suppressing, androgenic and anti-androgenic activities.
- US 2774777 discloses a process wherein, the starting material, 19-Norandrostene- 3, 17-dione is first protected with ethyl orthoformate to form enol-ether at the C-3 position as intermediate. Then, this intermediate is purified through solvent purification. Further base mediated acetylene is introduced at C-17 position followed by deprotection at the C-3 position. To obtain the final product, multiple purifications with ethyl acetate are conducted. The disadvantage of this process is protection at C-3, then deprotection in the last stage and multiple purifications at each stage to get the pure product with low yield. Therefore, due to multiple steps process with multiple purification steps and also low yield, this process is not commercially viable.
- US 2744122 discloses a process wherein A— 19-nor-androsten-17p-ol-3-one compound, a lower alkyl ether of estrone with an alkali metal in liquid ammonia followed by hydrolysis with a mineral acid and oxidation with chromic acid to form A -19-norandrosten-3, 17-dione, selectively forming a 3-enol ether of said dione and treating said ether with acetylene in the presence of an alkali metal alkoxide, followed by hydrolysis with a mineral acid. Therefore, due to multiple steps process and also low yield, this process is not commercially viable.
- US3655649 discloses a process wherein 9-hydroxy-3-keto-A-steroid is reacted with a secondary amine to form the corresponding 19-nor-3, 5-diene-3-amine.
- C-3 keto group is protected through secondary amine and column chromatography is used for purification which makes the process is more complex and commercially not viable.
- An object of the present invention is to provide a process for the preparation of 19- Norethisterone of Formula-I that addresses one or more deficiencies mentioned in the prior art documents.
- the present invention provides a one-pot process for the preparation of 19- Norethisterone of Formula-I with high yield and high purity.
- the one-pot process is simple, economical, user-friendly and commercially viable.
- the process for the preparation of 19- Norethisterone of Formula-I comprises the step of:
- the present invention discloses a single pot process for the preparation of 19- Norethisterone of Formula-I, comprising the ste s of:
- the process of the present invention may be suitably started from the compound of formula II, known by its IUPAC name (8R,9S,10R,13S,14S)-13-methyl-l,2,6,7,8,9,10,l 1,12,13, 14,15,16- dodecahydro-lH-cyclopenta[a]phenanthrene-3,17(2H,6H)-dione and hereinafter referred to as 19-Norandrostenedione (formula II) and leads to formation of 19 -Norethisterone of Formula-I known by its IUPAC name (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl- 6,7,8,9,10,11,12, 14, 15, 16-dodecahydro-lH-cyclopenta[a]phenanthren-3(2H)-one.
- IUPAC name 8R,9S,10R,13S,14S,17R
- a solution comprising 19-Norandrostenedione of Formula II may be contacted with the solution comprising metal acetylide at temperature not exceeding 5°C, preferably between -5°C to 5°C, more preferably 0°C + 2°C, and most preferably 0°C + 1°C, to get a first stage reaction solution comprising 19-Norethisterone of Formula I and free metal.
- the solution of 19-Norandrostenedione of Formula II comprises a solvent selected from a group consisting of tetrahydrofuran (THF), toluene, and dioxane; with tetrahydrofuran being the preferred choice.
- THF tetrahydrofuran
- toluene toluene
- dioxane dioxane
- the solution comprising metal acetylide is obtained by dissolving the metal acetylide in a solvent selected from a group consisting of tetrahydrofuran, toluene, and dioxane; with tetrahydrofuran being the preferred choice.
- the solution comprising metal acetylide is obtained by in- situ reaction of the first base with an acetylene yielding stream.
- the first base is taken in form of a solution comprising a solvent selected from a group consisting of tetrahydrofuran, toluene and dioxane; with tetrahydrofuran being the preferred choice; and the first base is selected from the group consisting of potassium t-butoxide, potassium hydroxide, lithium hydroxide, sodium t-butoxide and sodium hydroxide; with potassium t-butoxide being the preferred choice.
- the acetylene yielding stream is acetylene.
- the method further comprising adding an acetylene yielding stream to the first stage reaction solution to convert the free metal thus formed to further metal acetylide, wherein the further metal acetylide reacts with 19-Norandrostenedione to form 19- norethisterone of Formula-I.
- the addition of acetylene yielding stream is carried out until 19-Norandrostenedione gets depleted to at least 50%, preferably gets depleted to at least 75%, more preferably gets depleted to at least 90%, most preferably gets depleted to at least 99.5% of the original amount added.
- an acid is added to the first stage reaction solution to obtain a second stage reaction solution.
- the acid is added to the first stage reaction solution at a temperature of not exceeding 20°C, preferably between 10°C to 20°C, more preferably 15°C + 3°C, and most preferably 15°C + 1°C.
- the temperature of the second stage reaction solution is increased to a temperature not exceeding 45°C, preferably between 35°C to 45°C, more preferably 40°C + 2°C, and most preferably 40°C + 1°C.
- the acid is selected from a group consisting of hydrochloric acid, acetic acid, and trifluoro acetic acid.
- hydrochloric acid is the acid.
- the extraction of 19-Norethisterone of Formula I is done from the second stage reaction solution by use of an organic solvent selected from the group consisting of methyl isobutyl ketone, dichloromethane (DCM), ethyl acetate and toluene.
- the organic solvent is preferably methyl isobutyl ketone.
- a pH value of mother liquor that comprises the second stage reaction solution and the organic solvent
- a second base may be used.
- the second base may be selected from a group consisting of sodium bicarbonate, potassium bicarbonate, potassium carbonate and sodium carbonate.
- sodium bicarbonate is the second base.
- step (ii) wherein in step (ii), the purification of 19- Norethisterone of Formula-I is performed in presence of an organic solvent selected from a group consisting of methanol, ethanol and isopropanol; with methanol being the preferred organic solvent.
- an organic solvent selected from a group consisting of methanol, ethanol and isopropanol; with methanol being the preferred organic solvent.
- the compound of formula I may be used as important starting material/ intermediate for the synthesis of active materials.
- the compound of formula I may be optionally purified to obtain a pure compound. Such purification may be done by means of refluxing and subsequently washing with alcohol.
- single pot process for the preparation of 19- norethisterone of Formula-I comprises of:
- the process for the preparation of 19- Norethisterone of Formula-I comprises of sequential steps of:
- step (iii) adding an acetylene yielding stream to the solution of step (ii) to form metal acetylide therein;
- step (iv) adding 19-Norandrostenedione to the solution of step (iii) while maintaining the temperature at not more than 5°C such that 19-Norandrostenedione reacts with the metal acetylide to form 19-norethisterone of Formula-I and free metal;
- step (v) adding an acetylene yielding stream to the solution of step (iv) to convert the free metal thus formed to further metal acetylide, wherein the further metal acetylide reacts with 19- Norandrostenedione to form 19-norethisterone of Formula-I, the addition of acetylene yielding stream is carried out until 19-Norandrostenedione gets depleted to at least 50%, preferably gets depleted to at least 75%, more preferably gets depleted to at least 90%, most preferably gets depleted to at least 99.5% of the original amount added;
- step (vi) gradually adding acid to a solution of step (v) and raising the temperature to not more than 45°C;
- step (vii) adding an organic solvent to a solution of step (vi), stir and separate an organic layer thus formed;
- the process for the preparation of 19- Norethisterone of Formula- 1 comprises of sequential steps of:
- step (ii) adding an acetylene yielding stream to the solution of step (i) to convert the free metal thus formed to further metal acetylide, wherein the further metal acetylide reacts with 19- Norandrostenedione to form 19-norethisterone of Formula-I, the addition of acetylene yielding stream is carried out until 19-Norandrostenedione gets depleted to at least 50%, preferably gets depleted to at least 75%, more preferably gets depleted to at least 90%, most preferably gets depleted to at least 99.5% of the original amount added;
- step (iii) gradually adding acid to a solution of step (ii) and raising the temperature to not more than 45°C;
- step (iv) adding an organic solvent to a solution of step (iii), stir and separate an organic layer thus formed;
- the amount of metal acetylide needed can be substantially lesser than the stoichimetric amount needed for conversion of 19-Norandrostenedione to the compound of formula I.
- the amount of the first base needed can be substantially lesser than the stoichiometric ratio needed for conversion of 19-Norandrostenedione to the compound of formula I.
- the process of the present invention is single pot and avoids multiple steps.
- the process of the present invention involves th e use of economic and environment- friendly reagents that will give highly pure material and cost-effective process.
- Example-1 Process for the preparation of Norethisterone of Formula-1
- 19-Norandrostenedione should be less than 0.50%, added 10L of purified water at 5°C+ (5°C), added 30L of hydrochloric acid at 15°C+ (5°C), raised the temperature up to 40°C+ (5°C), stir for 30min., added 100L of methyl isobutyl ketone (10 volume) and 100L of purified water(10 volume), stir and separate organic layer.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
La présente invention concerne un procédé en pot unique pour la synthèse de 19-Noréthistérone de formule (I), comprenant la mise en contact de 19-Norandostene-3,17-dione de formule (II) avec une première base, un gaz/solution organique et un acide pour obtenir la 19-Noréthistérone de formule (I); et la purification de la 19-Noréthistérone de formule (I) ainsi obtenue par reflux et ensuite lavage avec un solvant organique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201711012365 | 2017-04-06 | ||
IN201711012365 | 2017-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018185783A1 true WO2018185783A1 (fr) | 2018-10-11 |
Family
ID=63712771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2018/050196 WO2018185783A1 (fr) | 2017-04-06 | 2018-04-06 | Nouveau procédé de préparation de 19- norstéroïdes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018185783A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5371052A (en) * | 1976-12-07 | 1978-06-24 | Mitsubishi Chem Ind Ltd | Purification of 19-norethisterone |
JPS588096A (ja) * | 1981-07-08 | 1983-01-18 | Mitsubishi Chem Ind Ltd | 19−ノルエチステロンの製法 |
-
2018
- 2018-04-06 WO PCT/IN2018/050196 patent/WO2018185783A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5371052A (en) * | 1976-12-07 | 1978-06-24 | Mitsubishi Chem Ind Ltd | Purification of 19-norethisterone |
JPS588096A (ja) * | 1981-07-08 | 1983-01-18 | Mitsubishi Chem Ind Ltd | 19−ノルエチステロンの製法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10000524B2 (en) | Synthesis of estetrol via estrone derived steroids | |
SU1340593A3 (ru) | Способ получени производных @ @ 19-норстероидов | |
CA1310630C (fr) | 13-ALKYL-11 .beta.-PHENYLGONANES, LEUR FABRICATION ET PREPARATIONS PHARMACEUTIQUES EN CONTENANT | |
US20060111577A1 (en) | Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates | |
WO1988002753A2 (fr) | Steroides 9-alpha-hydroxy et procede de preparation desdits steroides | |
EP1945618A2 (fr) | Procede de preparation de letrozole | |
EP1242444B1 (fr) | PROCEDE DE PREPARATION DE 17$g(a)-ACETOXY-11$g(b)- 4-N,N-(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIAIRES UTILISES PAR CE PROCEDE ET PROCEDES DE PREPARATION DE TELS INTERMEDIAIRES | |
EP1490390A2 (fr) | Spirolactonisation c-17 et oxydation 6,7 de steroides | |
EP1776378B1 (fr) | Procédé de fabrication de dérivés 2-substitués d"estrone et d"estradiol | |
JP2021183627A (ja) | 11−メチレンステロイドの製造のための方法および新規な中間体 | |
WO2018185783A1 (fr) | Nouveau procédé de préparation de 19- norstéroïdes | |
AU2008248222B2 (en) | Process for preparing aromatase inhibitors | |
US9012667B2 (en) | Process for introducing a double bond into position 15, 16 of a steroid | |
HU196430B (en) | Process for producing 17-alpha-ethinyl-17-beta-hydroxy-18-methyl-4,15-estradien-3-one | |
NO327095B1 (no) | Fremgangsmate for fremstilling av 7alfa-metylsteroider | |
JPS6229439B2 (fr) | ||
CA2427632C (fr) | Methode de production de 4-(17-substitution en alpha-3-oxoestra-4,9-dien-11-beta-yl)benzaldehyde-(1e ou 1z)-oximes | |
WO2011132045A2 (fr) | Procédé de préparation de dienogest sensiblement dépourvu d'impuretés | |
WO2005095431A1 (fr) | MÉTHODE DE PRODUCTION DU DÉRIVÉ PREGNANE- 5a | |
US20060014973A1 (en) | Processes for the preparation of 16beta-alkoxy, 17alpha-hydroxy steroids and steroidal 16beta, 17alpha-diols from 16alpha, 17alpha-epoxy steroids | |
GB2087892A (en) | Stereoselective synthesis of 3-amino-20-oxygenated-5a-pregnanes via novel pregn-17(20)-ene intermediates | |
ITMI20000918A1 (it) | Processo per la preparazione di un precursore di tibolone e di estradiol derivati strutturalmente correlati. | |
AU4918697A (en) | Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18781897 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18781897 Country of ref document: EP Kind code of ref document: A1 |